Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3174 | Standard Of Care (SOC) Wiki | 1.00 |
drug2879 | Rivaroxaban Wiki | 0.41 |
drug2557 | Placebo oral tablet Wiki | 0.17 |
Name (Synonyms) | Correlation | |
---|---|---|
D013577 | Syndrome NIH | 0.10 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
D018352 | Coronavirus Infections NIH | 0.03 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to evaluate the efficacy and safety of the metformin glycinate and standard treatment of the hospital in hospitalized patients with Severe Acute Respiratory Syndrome secondary to SARS-CoV2.
Description: Assess differences in SARS-CoV-2 viral load between participants that receive placebo vs metformin glycinate
Measure: Viral load Time: Day 0 to Day 28 or patient discharge dayDescription: Clinical status assessed by measurement of consciousness level: alertness
Measure: consciousness level Time: Day 0 to Day 28 or patient discharge dayDescription: Clinical status assessed by measurement of axillary body temperature in °C: <37.2.
Measure: temperature Time: Day 0 to Day 28 or patient discharge dayDescription: Clinical status assessed by measurement of systolic blood pressure in mmHg: >90.
Measure: systolic blood pressure Time: Day 0 to Day 28 or patient discharge dayDescription: Clinical status assessed by measurement of oxygen saturation in %: >90.
Measure: Oxigen saturation Time: Day 0 to Day 28 or patient discharge dayDescription: Clinical status assessed by measurement of heart rate in beats per minute: <100 bpm.
Measure: Heart rate Time: Day 0 to Day 28 or patient discharge dayDescription: Clinical status assessed by measurement of respiratory rate in breaths per minute: <24 bpm,
Measure: respiratory rate Time: Day 0 to Day 28 or patient discharge dayDescription: Assess length of hospitalization
Measure: Days of hospitalization Time: Day 0 to Day 28 or patient discharge dayDescription: Assess length of supplementary oxygen
Measure: Days of supplementary oxygen if applies Time: Day 0 to Day 28 or patient discharge dayDescription: Assess length of mechanical ventilation
Measure: Days of supplementary mechanical ventilation Time: Day 0 to Day 28 or patient discharge dayDescription: Assess by incidence of Grade 3, Grade 4, and Serious Adverse Events (AEs)
Measure: Toxicity of study drug assessed by incidence of adverse events (grade 3 or 4) Time: Day 0 to Day 28 or patient discharge dayDescription: Changes in serum levels from security laboratories compared to baseline levels and between groups.
Measure: Changes in laboratory test results Time: Day 0 to Day 28 or patient discharge dayAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports